AbbVie Inc. (NYSE: ABBV ) seems to have bucked the trend of health care weakness quite well. In the below chart, you can see that the stock has advanced around 18% YTD. Furthermore, AbbVie has fully recovered from Liberation DayI'm a full-time investor with a strong focus on the tech sector. I graduated with a Bachelor of Commerce Degree with Distinction, major in Finance. I'm also a proud lifetime member of the Beta Gamma Sigma International Business Honor Society. My core values are: Excellence, Integrity ...

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TS ...

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TS ...

Company Overview - Protalix BioTherapeutics (PLX) is a commercial-stage biotech company focused on recombinant therapeutic proteins [1] - The company utilizes its proprietary plant cell-based ProCellEx technology [1] Product Portfolio - Protalix has two approved enzyme replacement therapies: 1) Elfabrio for Fabry disease 2) Elelyso for Gaucher disease [1]

Asia Insights Global Markets Research Economics - Asia ex-Japan China: Policymaking amid a stock market rally and growth slowdown As economists we do not forecast stock markets, but we closely watch their impact on policymaking and economic activity. We believe that China's stock market rally since late September last year has been primarily driven by solid fundamentals. However, based on what previously happened, the boom has the potential to lead to a rise in irrational exuberance, an increase in leveragi ...

Core Viewpoint - Iovance Biotherapeutics, despite its innovative drug Amtagvi for advanced melanoma, faces challenges in stock performance and operational execution [1][2]. Company Overview - Iovance Biotherapeutics is a small-cap biotech company known for developing Amtagvi, the first approved treatment for advanced melanoma [1]. - The manufacturing and administration process of Amtagvi is complex, requiring tumor samples from patients to extract T cells for lab growth, followed by patient-specific infusions [4]. Financial Performance - In Q2, Iovance reported approximately $60 million in revenue, nearly double from the previous year, primarily driven by Amtagvi sales [6]. - For fiscal 2025, the company anticipates total product revenue between $250 million and $300 million, predominantly from Amtagvi [6]. Market Potential - Amtagvi is expected to gain approval in additional regions, including Canada and Europe, within the next 12 months, potentially expanding the market significantly [7]. - The U.S. market for Amtagvi remains largely untapped, with only over 100 patients treated compared to the 8,000 annual melanoma deaths [8]. - There are opportunities for label expansions into other cancer indications, which could further increase the target market for Amtagvi [9]. Challenges - The complex and costly nature of Amtagvi poses challenges for Iovance in achieving profitability and market traction [10]. - The company ended Q2 with approximately $307 million in cash, which is projected to last until Q4 of the following year, indicating potential financial strain [11]. - Clinical and regulatory hurdles could negatively impact the stock price and overall company performance [12].

Group 1 - The FDA decision on ONS-5010 (Lytenava) is imminent, marking a critical inflection point for Outlook Therapeutics (OTLK) [1] - ONS-5010 has already been validated in Europe, indicating potential for market acceptance [1] - The focus is on identifying biotechnology companies that innovate through unique mechanisms, first-in-class therapies, or platform technologies [1] Group 2 - The analysis emphasizes the importance of evaluating the science behind drug candidates, competitive landscape, clinical trial design, and market opportunities [1] - The biotech sector is characterized by the potential for breakthrough science to yield significant returns, necessitating careful scrutiny [1]

How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating ‘Butterfly Skin Disease’ https://t.co/F924ACA3z3 https://t.co/TetXgntzaP ...

NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submi ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...